New technique ‘could reduce breast cancer screening recall rate’

A new breast cancer detection technique has the potential to reduce the rate at which women are called back for further examinations, according to a new study.

In 2011, the US Food and Drug Administration (FDA) approved digital breast tomosynthesis (DBT) for use with full-field digital mammography (FFDM) in breast imaging. DBT uses a scanner that rotates partially around the breast, providing individual images of thin layers of tissue.

The Radiological Society of North America (RSNA) explained that when used with FFDM, DBT has been shown to improve cancer detection and reduce callbacks for additional examinations.

However, the combination of the two methods requires a second radiation exposure to the breast, while also slightly increasing the time a patient spends in breast compression.

Researchers have been exploring a relatively new approach in which the DBT images are used to create a synthesised 2-D (s2D) compilation image. The method has the potential to render FFDM unnecessary.

Dr Jacqueline Holt, director of Breast Imaging at Christiana Care Health System’s Helen F Graham Cancer Center and Research Institute, in Newark, Delaware, said: “The adoption of s2D mammography combined with DBT into screening programs would limit radiation exposure to the patient, and, on the basis of our results, may improve clinical performance.”ADNFCR-2094-ID-801832673-ADNFCR